Prognostic value of platelet to lymphocyte ratio in predicting survival of patients with metastatic castration-resistant prostate cancer receiving abiraterone acetate: An evidence-based case report and review of literature

Oliver E. Yausep, Raksheeth Agarwal, Rifqha Aulina, Anthony E. Wijaya, Ilonka Amaia, Addina W. Moekti, Ikhwan Rinaldi, Agus Rizal A.H. Hamid

Research output: Contribution to journalArticlepeer-review

Abstract

Platelet to lymphocyte ratio (PLR) is a candidate prognostic marker for metastatic castration-resistant prostate cancer patients receiving abiraterone acetate and evidence demonstrates that a high PLR is associated with poor survival. More studies are required to verify current findings and establish a definite cutoff point.

Original languageEnglish
Pages (from-to)1585-1590
Number of pages6
JournalClinical Case Reports
Volume7
Issue number8
DOIs
Publication statusPublished - 1 Jan 2019

Keywords

  • abiraterone
  • lymphocyte
  • metastatic Castration-Resistant Prostate Cancer
  • platelet
  • platelet to lymphocyte ratio
  • prostate cancer

Fingerprint Dive into the research topics of 'Prognostic value of platelet to lymphocyte ratio in predicting survival of patients with metastatic castration-resistant prostate cancer receiving abiraterone acetate: An evidence-based case report and review of literature'. Together they form a unique fingerprint.

Cite this